Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

Jun. 03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
Jun. 03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

Jun. 03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
Jun. 03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
Jun. 03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
May. 20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
24-03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
24-01-29	CoTec Holdings Outlines Key Targets For 2024	MT
24-01-03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
23-10-10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
23-10-10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
23-10-02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
23-09-14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
23-09-14	CoTec Holdings, Mkango To Form US Joint Venture	MT
23-06-30	Kings Chapel Increases Stake In CoTec Holdings	MT

May. 06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
16-08-31	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
16-08-29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
16-08-15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
16-08-12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+1.76%	+3.88%	+46.85%	+101.12%	69.69B
ARGENX SE	+2.29%	+1.43%	+38.39%	+77.03%	61.24B
INSMED INCORPORATED	+1.14%	-2.59%	-14.37%	+365.92%	26.77B
BIONTECH SE	+2.95%	+2.34%	+0.52%	-12.74%	24.07B
GENMAB A/S	+1.49%	+7.73%	+26.85%	-15.89%	20.39B
PHARMAESSENTIA CORPORATION	-0.83%	-9.47%	+174.16%	+295.44%	15.72B
EXELIXIS, INC.	+3.01%	+1.85%	+44.63%	+168.18%	14.07B
SUMMIT THERAPEUTICS INC.	+2.43%	+4.24%	-2.05%	+847.59%	13.8B
MADRIGAL PHARMACEUTICALS, INC.	+1.00%	+0.24%	+28.02%	+203.83%	12.22B
Average	+1.52%	+0.66%	+38.11%	+225.61%	28.66B
Weighted average by Cap.	+1.82%	+1.73%	+36.71%	+163.30%